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The completion and proper assessment of prospective, randomized controlled trials is essential for best medical
practice. However, even though randomized trials are generally considered the pinnacle of evidence-based medi-
cine, they are not infrequently poorly designed, implemented with inadequate quality control, and/or are subject
to inappropriate interpretation or generalization, resulting in suboptimal clinical care and/or future investigative
directions. The present report describes the most common and egregious misrepresentations from randomized
trials, many of which may be attributed to the fallacies that arise from underpowered studies, resulting in overly
optimistic or unwarranted conclusions. Caution is necessary when assessing composite outcomes, secondary
end points, subgroup analyses, and the results of meta-analysis and meta-regression. Sponsors and investigators
must accept responsibility for optimizing the design and execution of clinical trials, and practitioners, guidelines
committees, editors, and regulators must critically interpret the data and literature arising from such studies. It
is hoped that the principles embodied in the present commentary will spur improved design of future random-
ized trials and thoughtful critical appraisal by health care providers. (J Am Coll Cardiol 2010;55:428–31)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.066e
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q“A p value is no substitute for a brain.”
—Anonymous
he practice of medicine comprises endless choices by
hysicians on behalf of our patients. Such decisions are
ased on knowledge gained from randomized controlled
rials (RCTs), nonrandomized studies, personal and shared
xperiences, and common sense. By avoiding biases in
atient selection between experimental and control groups,
he prospective RCT is considered the highest level of
cientific evidence (1). RCTs also typically have the greatest
egulatory oversight and most robust study processes (e.g.,
n-site data monitoring, independent event adjudication
nd data safety monitoring, and blinded core laboratories).
owever, RCTs are expensive, labor intensive, and time-
onsuming, and the results apply only to the patients
nrolled and to the specific drugs, devices, and procedures
ested. Relatively few questions are addressed by RCTs, and
he standard of care evolves, rendering some RCTs in part
bsolete. Many decisions are, therefore, based on observa-
ional evidence and personal experience (anecdotal medi-
ine). Unfortunately, because statistical methods cannot
ompletely adjust for unmeasured confounders, such non-
andomized studies may yield erroneous conclusions (Fig. 1)
2,3), and thus should not generally be used for comparative
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Manuscript received June 17, 2009; accepted June 21, 2009.ffectiveness analysis. However, observational registries in
arge, unselected populations are useful to document practice
atterns and quantify the incidence of low frequency events.
Despite the advantages of RCTs, their design, imple-
entation, analysis, reporting, and subsequent clinical in-
erences can sometimes be seriously flawed. Accordingly,
hysicians should interpret the literature critically, recogniz-
ng the nuanced limitations inherent in RCTs. In this issue
f the Journal, Kaul and Diamond (4) describe numerous
ommon pitfalls of RCTs. While their examples may
timulate vigorous healthy debate, their report’s underlying
rinciples are well reasoned and should be required reading
or health care providers and other professionals involved in
rganizing or interpreting clinical trials.
Many issues addressed by Kaul and Diamond (4) revolve
round adequate power. Any RCT should require a pre-
pecified primary end point and a sample size powered to
emonstrate either superiority or noninferiority for the new
reatment. Small underpowered trials are prone to either
lpha error (false positives, with potential publication bias)
5) or beta error (false negatives) (6). Importantly, the
agnitude of the treatment effect assumed should be based
n realistic expectations. For example, there is little reason
o expect that N-acetylcysteine should virtually eliminate
adiocontrast nephropathy. Nonetheless, an underpowered
rial demonstrating an 89% reduction (7) prompted several
dditional (underpowered) trials, not surprisingly resulting
n conflicting outcomes and publication bias (8). We doubt
hat Bayesian methods add much insight to standard fre-
uentist methods, except conceptually they do help shrink
mplausibly large treatment effects in small trials. Bayesian
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owever, permit smaller studies to be performed while
reserving power, thus enhancing clinical trial efficiency (9),
lthough at the risk of complicating clinical interpretation.
The principal interpretation of an RCT focuses on the
ingle powered primary end point; additional observations
hould be hypothesis generating unless pre-specified and
ppropriately powered with statistical adjustment to pre-
erve alpha. Overinterpreting the results of secondary end
oints or inherently underpowered subgroups risks distor-
ive conclusions, especially regarding rare safety end points,
or example, death or stent thrombosis, which can falsely
uide patient care decisions or subsequent investigative
irections. For example, the unexpected observation of
mproved survival with the complement inhibitor pexeli-
umab during primary percutaneous coronary intervention
n acute myocardial infarction (AMI) in a pilot trial that
ailed to demonstrate infarct size reduction (10) led to the
Figure 1 Comparative Mortality Rates for DES and BMS in Acu
(A) Two-year mortality among 1,298 propensity-matched pairs of patients with ST-s
taxel or sirolimus drug-eluting stents (DES) or bare-metal stents (BMS) at 21 Mass
days, a time before any known benefits of DES compared with BMS. This finding m
ized study. Adapted from Mauri et al. (2). (B) One-year mortality among 3,006 pat
to either paclitaxel-eluting stents (PES) or BMS at 123 hospitals in 11 countries. M
from Stone et al. (3).ostly performance of an 8,500-
atient RCT powered for mor-
ality, which was stopped pre-
aturely for futility (11). The
nterpretation of composite end
oints may be challenging if the
omponent end points are not
niformly affected by treatment,
r are of differing clinical importance. Few end points,
owever, are judged as equally devastating as death (12), and
arely can trials be powered for mortality (the GUSTO
Global Utilization of Streptokinase and Tissue-Type Plas-
inogen Activator for Occluded Coronary Arteries] trial,
or example, required 40,000 patients) (13). Presentation
f the individual component event rates is thus vital, and
ensible interpretation depends on the pattern observed.
eighted composite end points are conceptually interest-
ng, but given their subjectivity, are best reserved for
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
RCT  randomized
controlled trial
yocardial Infarction
nt elevation myocardial infarction treated at physician discretion with either pacli-
etts hospitals. Significantly lower mortality was present with DES, mostly by 30
ll be due to residual confounding by unmeasured variables in this nonrandom-
ith ST-segment elevation myocardial infarction randomly allocated in a 3:1 ratio
ty rates with DES and BMS were nearly identical at 30 days and 1 year. Adaptedte M
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n large trials, with pre-specification of those few groupings
f genuine interest, should be explored by statistical inter-
ction paying regard to multiple comparisons, and should
nly be considered hypothesis generating, requiring pro-
pective validation in future studies.
While we agree with most of Kaul and Diamond’s
rguments (4), several examples contained internal incon-
istencies. For example, the Stent-PAMI (Stent–Primary
ngioplasty for Myocardial Infarction) trial was too small
n  900) to raise serious concern regarding increased
ortality with stenting compared with balloon angioplasty
or AMI (especially with p  0.05). Subsequent trials (n 
,922 total) confirmed near-identical survival rates (14).
imilarly, regarding the comparative safety and efficacy of
rug-eluting versus bare-metal stents, studies in 12,000
andomized patients and 450,000 registry patients have
ow demonstrated that mortality and myocardial infarction
ates are comparable or reduced with drug-eluting stents
15–17). Kaul and Diamond (4) note that bleeding and
yocardial infarction rates tracked discordantly in 2 trials in
hich bivalirudin was compared with heparin plus glyco-
rotein IIb/IIIa inhibitors, arguing they should not have
een combined in a composite end point. Yet, 1-year
ortality with bivalirudin was significantly reduced among
atients with AMI (17) and also when pooled across 3 trials
overing the spectrum of coronary artery disease in23,000
atients, reflecting the long-term impact of major hemor-
hagic complications on mortality (18). No single study or
solated finding from an RCT should dictate the practice of
edicine; even large RCTs must be considered in context
ith the results from other high-quality studies.
Several additional key aspects of RCTs were not dis-
ussed by Kaul and Diamond (4). 1) Multicenter trials
fford greater credence and generalizability than single-
enter studies. 2) Double-blind trials are preferred to
ingle-blind trials, which are preferred to fully unblinded
tudies. However, unblinded trials, while often logistically
navoidable, can yield valid results if there is high compli-
nce with protocol procedures, appropriate efforts to mini-
ize bias, and use of blinded end point committees and core
aboratories. 3) Superiority trials provide stronger evidence
han noninferiority trials with active controls; the latter are
imited by the acceptability of the chosen noninferiority
argin (delta) and creep, which can occur when serial
oninferiority trials are performed, resulting in falsely de-
laring an inferior treatment equivalent to a prior standard
19). 4) Whether the patients enrolled and study processes
re generalizable to other settings requires careful consider-
tion. For example, an RCT evaluating an anticoagulant in
cute coronary syndrome patients managed conservatively
as little relevance to patients managed invasively. 5) The
uality of RCTs varies greatly in terms of their design,
onduct, and reporting. Studies of lesser quality and smaller
cope should not carry equal weight to large-scale compre-
ensive trials just because they are “randomized.” Also, theenefits from the robust quality control often present in
ndustry-sponsored trials, which for regulatory reasons em-
loy more rigorous data collection, monitoring, and inde-
endent oversight committees and core laboratories than do
ost investigator-sponsored studies, must be weighed
gainst concerns of potential bias in trial design, implemen-
ation, and reporting.
Also of concern is the ever-increasing number of meta-
nalyses being published (often in high-quality journals),
iven their inherent limitations and variable quality. Meta-
nalyses are frequently constructed from numerous under-
owered and flawed trials, leading to questionable “meta-
onclusions” that may well be wrong when compared with a
ubsequent large RCT (20). Random effects models are
ften utilized to account for heterogeneity between studies
hat should not have been grouped together in the first
lace, and provide undue weight to the results from small
rials (21). Network meta-analyses incorporate evidence
rom studies that do not directly compare the treatments of
nterest (22), representing in many cases a statistical leap too
ar. Meta-regression is a seriously flawed instrument; such
bservational associations of variations in effect between
rials are inevitably a very weak form of evidence (23).
espite these limitations, meta-analysis and meta-
egression are receiving unwarranted attention by journals,
uidelines committees, and payors.
We hope that the paper by Kaul and Diamond (4) and
his commentary will spur improved design of future RCTs
nd thoughtful critical appraisal by caregivers, editors, and
egulatory bodies. While it is true that “a p value is no
ubstitute for a brain,” neither is ignorance of sound clinical
nvestigation and statistical principles. Translating statistical
ndings into plain English will facilitate the appropriate
linical interpretation of RCTs (24). The implementation of
vidence from well-designed scientific studies into the
veryday practice of medicine is essential if clinical medicine
s to realize its full potential.
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ork, New York 10023. E-mail: gs2184@columbia.edu.
EFERENCES
1. Pocock SJ, Elbourne DR. Randomized trials or observational tribula-
tions? N Engl J Med 2000;342:1907–9.
2. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents
for acute myocardial infarction. N Engl J Med 2008;359:1330–42.
3. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents
versus bare-metal stents in acute myocardial infarction. N Engl J Med
2009;360:1946–59.
4. Kaul S, Diamond GA. Trial and error: how to avoid commonly
encountered limitations of published clinical trials. J Am Coll Cardiol
2010;55:415–27.
5. DeMaria AN. Publication bias and journals as policemen. J Am Coll
Cardiol 2004;44:1707–8.6. Altman DG, Bland JM. Absence of evidence is not evidence of
absence. BMJ 1995;311:485.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
431JACC Vol. 55, No. 5, 2010 Stone and Pocock
February 2, 2010:428–31 Randomized Trials, Statistics, and Clinical Inference7. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of
radiographic contrast agent-induced reductions in renal function by
acetylcysteine. N Engl J Med 2000;343:180–4.
8. Vaitkus PT, Brar C. N-acetylcysteine in the prevention of contrast-
induced nephropathy: publication bias perpetuated by meta-analyses.
Am Heart J 2007;153:275–80.
9. Guidance for the Use of Bayesian Statistics in Medical Device Clinical
Trials. Available at: http://www.fda.gov/cdrh/osb/guidance/1601.pdf.
Accessed June 12, 2009.
0. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an
anti-C5 complement antibody, as adjunctive therapy to primary
percutaneous coronary intervention in acute myocardial infarction.
Circulation 2003;108:1184–90.
1. The APEX AMI Investigators. Pexelizumab for acute ST-elevation
myocardial infarction in patients undergoing primary percutaneous
coronary intervention. JAMA 2007;297:43–51.
2. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for
stroke. Pharmacoeconomics 2003;21:191–200.
3. The GUSTO Investigators. An international randomized trial com-
paring four thrombolytic strategies for acute myocardial infarction.
N Engl J Med 1993;329:673–82.
4. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting
versus balloon angioplasty for acute myocardial infarction. Int J Car-
diol 2007;119:306–9.
5. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of
drug-eluting and bare metal stents: comprehensive meta-analysis of Krandomized trials and observational studies. Circulation 2009;119:
3198–206.
6. Douglas PS, Brennan JM, Anstrom KJ, et al. Clinical effectiveness of
coronary stents in elderly persons. J Am Coll Cardiol 2009;53:
1629–41.
7. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during
primary PCI in acute myocardial infarction. N Engl J Med 2008;358:
2218–30.
8. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR. Bleeding, blood
transfusion, and increased mortality after percutaneous coronary inter-
vention. J Am Coll Cardiol 2009;53:2019–27.
9. Ware JH, Antman EM. Equivalence trials. N Engl J Med 1997;337:
1159–61.
0. LeLorier J, Grégoire G, Benhaddad A, et al. Discrepancies between
meta-analyses and subsequent large randomized, controlled trials.
N Engl J Med 1997;337:536–42.
1. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet
1992;338:1127–30.
2. Lumley T. Network meta-analysis for indirect treatment comparisons.
Stat Med 2002;21:2313–24.
3. Higgins JPT, Thompson SG. Controlling the risk of spurious findings
from meta-regression. Stat Med 2004;23:1663–82.
4. Pocock SJ, Ware JH. Translating statistical findings into plain En-
glish. Lancet 2009;373:1926–8.ey Words: results y megatrials y interpret.
